NewEdge Wealth LLC Sells 214 Shares of Atrion Co. (NASDAQ:ATRI)

NewEdge Wealth LLC lessened its stake in shares of Atrion Co. (NASDAQ:ATRI) by 16.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,108 shares of the medical instruments supplier’s stock after selling 214 shares during the quarter. NewEdge Wealth LLC’s holdings in Atrion were worth $420,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ATRI. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Atrion by 7.7% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,297 shares of the medical instruments supplier’s stock worth $128,908,000 after buying an additional 14,684 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Atrion by 0.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 145,792 shares of the medical instruments supplier’s stock worth $91,683,000 after buying an additional 772 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Atrion by 1.0% during the second quarter. BlackRock Inc. now owns 109,494 shares of the medical instruments supplier’s stock valued at $61,941,000 after buying an additional 1,046 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Atrion by 0.8% during the third quarter. Vanguard Group Inc. now owns 83,418 shares of the medical instruments supplier’s stock valued at $47,131,000 after acquiring an additional 653 shares in the last quarter. Finally, State Street Corp raised its holdings in Atrion by 2.9% in the 2nd quarter. State Street Corp now owns 35,443 shares of the medical instruments supplier’s stock worth $20,050,000 after acquiring an additional 1,011 shares during the last quarter. Institutional investors own 66.19% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Atrion from a “sell” rating to a “hold” rating in a research note on Friday, March 1st.

Atrion Stock Performance

Shares of NASDAQ:ATRI opened at $398.76 on Thursday. The firm has a market cap of $701.82 million, a price-to-earnings ratio of 36.15 and a beta of 0.60. The business has a 50-day simple moving average of $400.30 and a two-hundred day simple moving average of $365.10. Atrion Co. has a fifty-two week low of $274.98 and a fifty-two week high of $670.00.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. The firm had revenue of $43.58 million during the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were issued a dividend of $2.20 per share. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.21%. Atrion’s payout ratio is 79.78%.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.